We value your privacy

We use necessary cookies to make this site work, and Google Analytics to measure visits (it sets cookies and is not affected by the choices below). With your consent, we also use our own analytics cookies to understand how the site is used and improve it. Privacy policy

XOOBAY 数贝环球
金盒集团
金盒集团

金盒集团

Premier Elite

5
Products
0
Followers
2013
Established

Overseas Listing | Filing Status Table for Overseas Securities Issuance and Listing (as of September 21, 2023): 2 New Companies Added

Overseas Listing | Filing Status Table for Overseas Securities Issuance and Listing (as of September 21, 2023): 2 New Companies Added

Golden Box Group | IPO Advisory | US Listing |IPO|SPAC|RTO|US Listing|Professional US Listing Advisory Firm|US Stock Market Listing|

Today's Quick Overview of US Listing News!

On September 22, the CSRC updated the filing status table for domestic enterprises issuing securities and listing overseas (as of September 21, 2023). A total of 107 domestic enterprises have filed (excluding those that have completed), among which 72 plan to list in Hong Kong, 34 plan to list in the US, and 1 plans to list in Switzerland.

Last week, two new enterprises filed, one each for the US and Hong Kong. The two enterprises are: Xinbao Botong and Qinhong International.

On the same day, the CSRC International Department issued requests for supplementary materials to nine enterprises, two of which are planning to list in the US (Fendan Technology,Baird Medical Investment). Details are as follows:

1. SF Holding

Please provide supplementary explanations on the following matters, and ask lawyers to conduct verification and issue clear legal opinions:

1. In accordance with the requirements of the "Guidelines on Application of Regulatory Rules – Overseas Issuance and Listing No. 2: Guidelines on Content and Format of Filing Materials," please supplement information regarding your subsidiary engaged in "domestic express delivery business of letters" and the proportion of corresponding business revenue.

2. Regarding equity structure, please explain, considering factors such as debt repayment capacity, whether the pledge of your company's shares before and after this issuance may lead to a change in your controlling shareholder.

3. Regarding equity transfer, please explain the pricing basis and payment of relevant taxes and fees for the equity transfer conducted in March 2023 between your controlling shareholder, Shenzhen Mingde Holdings Development Co., Ltd., and Shenzhen Weishun Enterprise Management Co., Ltd.

4. Please supplement the regulatory opinions from the industry regulatory authorities regarding your subsidiary, SF Hengtong Payment Co., Ltd.

5. Regarding personal information protection and data security, please explain the scale and situation of personal information collected, used, analyzed, and stored by your company and subsidiaries, the arrangements or measures taken for personal information protection and data security, and whether they comply with national laws and regulations on personal information protection.

2. Fendan Technology (US Listing)

Please provide supplementary explanations on the following matters, and ask lawyers to conduct verification and issue clear legal opinions:

1. Please explain the standardized operation of your main business:

(1) Your main business includes providing loan facilitation services to operators in specific industries and financial institution clients. Please supplementarily explain whether your company invested self-raised funds as the source of loans during the loan facilitation process, whether the business constitutes financial or quasi-financial activities, whether it involves personal credit reporting business, and whether necessary business qualifications and licenses have been obtained;

(2) Whether the business development complies with the "Interim Measures for the Administration of Business Activities of Online Lending Intermediary Institutions," whether filing registration has been conducted and corresponding telecommunications business operating licenses obtained in accordance with Article 5 of these Measures, and whether there are any prohibited circumstances stipulated in Article 10 of these Measures;

(3) Whether business operations involve post-loan collection services, and whether there are situations where non-compliant methods are used for collection;

(4) During the reporting period, whether there were situations where regulatory measures were taken or penalties imposed by competent authorities on loan facilitation and post-loan collection businesses (if any); if so, the rectification status of relevant violations and whether they constitute substantive obstacles to this overseas issuance and listing;

(5) Based on the names, types (industry affiliation), revenue composition from these customers, and pricing basis of the top five customers in each year during the reporting period, please explain the specific cooperation model, business processes, and service content between your company and financial institutions or quasi-financial institutions; whether marketing, intermediary, and technical service income from the same customer can be accurately distinguished and whether it is linked to the scale of loan facilitation;

(6) Based on the names and types of the top five suppliers in each year during the reporting period, please explain the main cost composition;

(7) The scale of loan facilitation, the scale of self-raised fund investment and its sources (if applicable) in each year during the reporting period, and the proportion of fees charged by your company relative to loan interest;

(8) Whether your company has related party relationships with the aforementioned major customers and suppliers;

(9) Whether the major financial or quasi-financial institutions cooperating with your company during the reporting period experienced significant debt repayment risks or other operational abnormalities, and whether this caused material adverse effects on your company's business operations;

(10) Reasons for the changing trends in technical service fees and intermediary service fees within business income during the reporting period.

2. Please explain the scale of user information collected and stored by your online operation platform "Ai Fen Dan," data collection and usage, and the name of the platform operator; reasons for the significant discrepancy between disclosed data in filing materials and data on the "Ai Fen Dan" official website pages; whether there are situations of providing information to third parties; and arrangements or measures for personal information protection and data security before and after listing.

3. Please explain the basis for identifying the controlling shareholder, and whether the controlling shareholder and actual controller will change after this issuance.

4. Please explain the pricing basis for the transfer price when Shanghai Fendan's original shareholders transferred equity to Qingdao Zecan, the lawful payment of taxes and fees, and whether the equity transfer by natural person shareholders complies with the "Administrative Measures for Individual Income Tax on Equity Transfer Income (Trial)."

5. Please explain the reasons and compliance issues regarding the unpaid registered capital of your main domestic operating entity, Shanghai Fendan, and whether this causes material adverse effects on company business operations and debt repayment capacity.

3. Ma Long Dental

Please provide supplementary explanations on the following matters, and ask lawyers to conduct verification and issue clear legal opinions:

1. Regarding equity structure and changes, please explain the amounts, pricing basis, payment of consideration, and tax payments for all share changes during the reporting period.

2. Regarding major asset acquisitions, please explain: (1) Reasons, amounts, pricing basis, and related party relationships for multiple asset acquisitions during the reporting period; (2) Goodwill recognition, impairment status, and whether subsequent developments may cause material adverse effects on your company's financial condition, business operations, and this issuance and listing; (3) Whether there are benefit transfer behaviors in asset acquisitions.

3. Regarding personal information protection and data security, please explain:

(1) The status of APPs, mini-programs, public accounts, and other products developed and operated by your company and subsidiaries, whether they involve providing information content to third parties; if so, specify the type of information content and security protection measures for information content;

(2) The scale of user information collected and stored, data collection and usage, and arrangements or measures for personal information protection and data security before and after listing.

4. Regarding shares applying for "Full Circulation," please explain: whether the shares held by shareholders applying for "Full Circulation" are pledged, frozen, or subject to other disputes, and whether they have been disclosed in accordance with regulations; also, please explain the subsequent reduction plans of shareholders applying for "Full Circulation," and whether such arrangements may lead to significant changes in your company's equity structure, control rights, etc.

4. Baird Medical Investment Holdings Limited (US Listing)

Please provide supplementary explanations on the following matters, and ask lawyers to verify and issue clear legal opinions:

1. Regarding the controlling shareholder and actual controller, please explain:

(1) The situation of the ultimate penetration of the controlling shareholder, Baird Medical Investment Holdings Limited, to state-owned controlled or managed entities, collective organizations, natural persons, etc.;

(2) The status of pledges, freezes, litigation, arbitration, or other disputes regarding shares held by the actual controller or shareholders dominated by the controlling shareholder or actual controller (if any).

2. Regarding participating and holding companies, please explain:

(1) The standard basis for determining the main domestic operating entities;

(2) Whether the failure to fulfill tax declaration and withholding obligations for the fifth to ninth equity transfers of Baird Suzhou from 2017 to 2019 constitutes a substantive obstacle to this overseas listing, and the tax payment status for the tenth equity transfer;

(3) Conclusive opinions on the legality and compliance of historical equity changes of the main domestic operating entities.

3. Regarding corporate governance, please supplement the terms of office for board members.

4. Regarding main business, please explain:

(1) Whether the entrusted production behavior violates medical device management regulations, given that Baird Suzhou only holds a Class II medical device production license, while Nanjing Changcheng entrusted it to produce microwave ablation equipment that should be managed as Class III medical devices;

(2) Whether Hunan Baird Medical Technology Co., Ltd.'s main business involves the production of microwave ablation needles, and whether it holds corresponding qualification certificates;

(3) Whether microwave ablation needles and microwave thermal coagulation ablation needles are the same product; if not, please explain the specific differences;

(4) According to the "Guiding Principles for Registration Review of Microwave Ablation Equipment" (No. 93, 2021), when microwave ablation needles are registered separately, they should be managed as Class III medical devices referring to the microwave ablation host. Whether classifying microwave ablation needles as Class II medical devices by your company is consistent with the above regulations.

5. Regarding confidentiality and archive management, please explain the construction and operation of confidentiality and archive management systems for the issuer and other domestic operating entities besides the domestic operating entity Baird Suzhou, and the implementation status of relevant requirements under the "Provisions on Strengthening Confidentiality and Archive Management Work Related to Domestic Enterprises' Overseas Securities Issuance and Listing."

6. Regarding transaction compliance, please explain:

(1) The transaction price and pricing basis for the merger transaction between your company and ExcelFin Acquisition Corp., and the tax declaration and payment status in accordance with the "Announcement on Several Issues Concerning Corporate Income Tax on Indirect Property Transfers by Non-Resident Enterprises";

(2) In comparison with Point 2 of "V. Transactions of Assets of Domestic Enterprises" in the "Guidelines on Application of Regulatory Rules – Overseas Issuance and Listing No. 1," please explain whether the purchased assets are operating assets, whether ownership is clear, etc.

5. Sanhua Intelligent Controls

Please provide supplementary explanations on the following matters, and ask lawyers to conduct verification and issue clear legal opinions:

1. Considering factors such as the pricing of this GDR issuance, potential GDR investor structure, current investor feedback, A-share market valuation and liquidity, please evaluate and analyze the impact of converting GDRs into A-shares after the expiration of the lock-up period on trading and the market, and propose corresponding contingency plans.

2. Please supplementarily explain the changes in foreign investors' holdings of your company's equity during the reporting period and the reasons for such changes; please supplementarily explain the measures your company intends to take to continuously comply with foreign ownership ratio regulations during this GDR issuance and subsequent conversion period, and their operability.

Tianju Dihe

Please provide supplementary explanations on the following matters, and ask lawyers to verify and issue clear legal opinions:

1. Please list and explain the basis for determining prices and reasonableness of all share changes since becoming a joint-stock limited company.

2. Please list and detail the verification status of the number of shareholders and explain the basis.

3. Please explain the background, price fairness, and compliance status of multiple departed personnel joining Li Ju Liu He equity incentive plan, as well as the handling of relevant rights and interests after departure.

4. Please explain the progress of fulfilling state-owned shareholder identification management procedures, and the progress of canceling the value-added telecommunications business license.

5. JD Technology is both a major shareholder and a major customer of your company. Please explain independence, and the fairness of related-party transaction pricing.

6. Please explain the relevant situation of previously applying for A-share listing.

7. Please explain whether business operations involve collecting and using personal information; if so, please explain the scale of user information collected and stored, data collection and usage, and arrangements or measures for personal information protection and data security before and after listing.

8. Please explain whether the shares held by shareholders applying for "Full Circulation" are pledged, frozen, or subject to other disputes, and whether they have been disclosed in accordance with regulations; also, please explain the subsequent reduction plans of shareholders applying for "Full Circulation," and whether such arrangements may lead to significant changes in the issuer's equity structure, control rights, etc.

7. Jinyuan Hydrogen Energy

Please provide supplementary explanations on the following matters, and ask lawyers to conduct verification and issue clear legal opinions:

1. Regarding business independence:

(1) Please explain the independence status of your company from the parent company in terms of business, assets, personnel, organization, finance, etc.;

(2) Please completely explain the occurrence links, content, amount and proportion, fairness, and substitutability of various categories of related-party transactions;

(3) Please explain the proportion of overlapping customers and suppliers between your company and the parent company.

2. Please explain whether existing, under-construction, and raised-fund projects belong to "high energy consumption" or "high emission" projects, and provide relevant basis.

8. Viseon Pharma

Please provide supplementary explanations on the following matters, and ask lawyers to conduct verification and issue clear legal opinions:

1. Regarding shareholder information,

(1) In accordance with the "Guidelines on Application of Regulatory Rules – Overseas Issuance and Listing No. 2," explain the basic situation of the controlling shareholder line penetrating to natural persons, including but not limited to name, nationality, whether they hold permanent overseas residency rights, address;

(2) Explain the fulfillment of domestic regulatory procedures such as foreign exchange registration and outbound investment by domestic natural persons and domestic companies after penetration of Vivo Capital Fund IX; (3) Explain the reasons why the beneficial owners of the main domestic operating entities are not identified as the actual controllers of the company.

2. Regarding equity incentives, (1) Explain the reasons for inconsistency in the number of incentive recipients between the filing report and the legal opinion, whether external personnel exist; if so, please verify against the "Guidelines on Application of Regulatory Rules – Overseas Issuance and Listing No. 2"; (2) For those involving share incentives through offshore trusts, explain the trust establishment time, type and operation method, rights and obligations arrangements of each trust party, trust beneficiaries, and other specific details.

3. Regarding standardized operations, please explain:

(1) Independence from Ascendis Pharma in terms of personnel, business, assets, finance, etc., and explain the risk of your company's core technology relying on Ascendis Pharma, whether it constitutes a material impact on your company's independent R&D capability or sustainable operating capability, and whether it constitutes a substantive obstacle to this issuance and listing;

(2) The scale of personal information collected and stored, personal information collection and usage during the R&D process of domestic operating entities, whether there are situations of transmitting data overseas or providing personal information to third parties, whether it complies with relevant provisions of the "Measures for the Administration of Scientific Data," and explain arrangements or measures for information data protection before and after listing;

(3) Whether the business of domestic operating entities involves "development and application of human stem cells, gene diagnosis and treatment technologies" in the "Special Administrative Measures for Foreign Investment Access (Negative List)" (2021 Edition), and provide clear basis.

9. Sunho Biologics, Inc.

Please provide supplementary explanations on the following matters, and ask lawyers to verify and issue clear legal opinions:

1. In accordance with regulatory guidelines, please penetrate and explain the specific situation of upper-level natural person shareholders of shareholder No5XJR Limited.

2. Regarding the equity incentive plan, please explain: (1) The fulfillment of internal decision-making procedures for the issuer's equity incentives; (2) Whether OriTrue Limited is an equity incentive holding platform, whether Zhu Zhenfei is an incentive recipient; if so, please verify and explain relevant situations in accordance with the "Guidelines on Application of Regulatory Rules – Overseas Issuance and Listing No. 2."

3. Please explain the consideration, pricing basis and fairness, and lawful payment of taxes and fees for the equity transfer of Shenghe China, and issue clear conclusive opinions on the compliance of Shenghe Pharmaceutical obtaining Shenghe China's equity.

4. Please explain the reasons and compliance issues regarding the unpaid registered capital of main domestic operating entities Shenghe China, Shenghe Pharmaceutical, and Shenghe Zhejiang, and whether this causes material adverse effects on company business operations and debt repayment capacity.

5. Please further self-inspect whether the business of domestic operating entities involves the development and application of human stem cells, gene diagnosis and treatment technologies in the "Special Administrative Measures for Foreign Investment Access (Negative List)" (2021 Edition), and provide clear basis.

6. Please explain the reasons for the last-minute investment by Huzhou Ansheng and Huzhou Anhe in the issuer on the day before submitting listing documents, as well as the consideration, pricing basis, fairness and reasonableness of this capital increase, whether there is benefit transfer, and issue clear conclusive opinions.

7. Regarding business independence, Nanjing Bode Bio-Pharmaceutical Co., Ltd., controlled by the issuer's actual controller, is one of the issuer's top five suppliers and provides high-value loans to the issuer. Please explain:

(1) The reasons, compliance, and reasons and rationality for unconditional waiver of loans provided by Nanjing Bode Bio-Pharmaceutical Co., Ltd. to the issuer;

(2) Independence from Nanjing Bode Bio-Pharmaceutical Co., Ltd. in terms of personnel, business, assets, finance, etc., and explain whether your company has significant dependency risks, and whether it constitutes a substantive obstacle to this issuance and listing.

Chinese concept stocks' US listings rebound,the approval process for enterprises' overseas issuance and listing filings has accelerated,2023yearUS stock market has seen strong gains,Chinese companies' confidence in listing in the US is also growing. Jinhe Group's Xiaojin will share daily hot information on US listings to help enterprises soar in their listing journey!

Disclaimer: Some information in this article is sourced from the internet. The content of this article is for sharing purposes only. If there are any issues regarding the content or copyright, please contact us and we will handle it as soon as possible.

尾图新.jpg

Originally published on 金盒企业管理集团